BioCardia Files 8-K: Regulation FD & Exhibits
Ticker: BCDA · Form: 8-K · Filed: Aug 21, 2024 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Aug 21, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, regulation-fd, exhibits
TL;DR
BioCardia filed a routine 8-K for disclosures and exhibits, no major news.
AI Summary
BioCardia, Inc. filed an 8-K on August 21, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form.
Why It Matters
This filing indicates BioCardia is adhering to its reporting obligations with the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard procedural report and does not indicate any new risks or material changes for the company.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- August 21, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38999 (filing_id) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing for BioCardia, Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits, as indicated in the filing information.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on August 21, 2024.
In which state was BioCardia, Inc. incorporated?
BioCardia, Inc. was incorporated in Delaware.
What is the Commission File Number for BioCardia, Inc.?
The Commission File Number for BioCardia, Inc. is 001-38999.
Does this 8-K filing disclose any specific new financial results or material events?
Based on the provided text, this 8-K filing is for Regulation FD Disclosure and Financial Statements and Exhibits, and does not specify any new financial results or material events beyond these categories.
Filing Stats: 490 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-08-21 07:00:31
Key Financial Figures
- $0.001 B — ich registered Common Stock, par value $0.001 BCDA The Nasdaq Capital Market Warrant
Filing Documents
- bcda20240821_8k.htm (8-K) — 29KB
- ex_717095.htm (EX-99.1) — 15KB
- 0001437749-24-027428.txt ( ) — 193KB
- bcda-20240821.xsd (EX-101.SCH) — 4KB
- bcda-20240821_def.xml (EX-101.DEF) — 13KB
- bcda-20240821_lab.xml (EX-101.LAB) — 17KB
- bcda-20240821_pre.xml (EX-101.PRE) — 13KB
- bcda20240821_8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 21, 2024, BioCardia, Inc. (the "Company") issued a press release announcing the FDA has approved a protocol amendment for the CardiAMP Heart Failure II Trial, its confirmatory Phase 3 trial of its autologous CardiAMP cell therapy product candidate for patients with ischemic heart failure of reduced ejection fraction. The protocol amendment allows patients who would have previously been excluded from treatment to receive additional cell deliveries to achieve the same target minimum dosage utilizing a treatment plan informed by the preprocedural CardiAMP Cell Population Analysis. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 BioCardia, Inc. press release dated August 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: August 21, 2024